Dr. Crispin is based in the Oxford Glycobiology Institute within the Department of Biochemistry. His research interests lie in the development of carbohydrate-based vaccines against HIV and the development of therapeutic antibodies. He is interested in how the carbohydrates attached to proteins (glycosylation) can be controlled and how such techniques can be exploited in the development of vaccines and therapeutics. For example, his group recently demonstrated a new approach for enhancing therapeutic antibodies against cancer (Baruah et al. J. Mol. Biol. 2012). His work towards an HIV vaccine is based on targeting the carbohydrate coat of HIV that shields the virus.